Skip to Content
Contact DCTD
Show menu
Search this site
Last Updated: 10/17/2023
NCI Webinar Series: Novel Chemical Approaches for Targeting Fusion Oncoproteins

ctDNA in Cancer Treatment and Clinical Care

DCTD's Cancer Diagnosis Program hosted a workshop on September 14-15, 2023.

Recordings of the presentations are posted below.

Workshop Goals

This workshop focused on the current landscape and requirements for the future of ctDNA in the treatment and management of solid tumors, and how the scientific community can best assess the value of ctDNA technology.

Workshop Design

More than 30 speakers gave 15-minute presentations on the following topics:

  • Statistician and patient perspectives on ctDNA
  • ctDNA for management of solid tumors in the neoadjuvant and adjuvant settings
  • ctDNA post-treatment and MRD surveillance of solid tumors
  • ctDNA for treatment of metastatic solid tumors
  • The challenges of ctDNA as a biomarker
  • Applications beyond DNA mutations and blood
  • Advances in technology, assays, and clinical translation

Workshop Recordings and Agenda

Day 1 Recording External Link
Day 2 Recording External Link

Day 1

Statistician and Patient Perspectives on ctDNA
ctDNA clinical trial designs Dr. Lisa McShane
Patient perspective on ctDNA in treatment management and care Patty Spears
Panel Q&A with Dr. McShane and Patty Spears
ctDNA for Management of Solid Tumors in the Neoadjuvant Setting
Perioperative ctDNA dynamics with hepatectomy for colorectal liver metastases Dr. Arvind Dasari
ctDNA to detect residual disease after neoadjuvant therapy in breast cancer Dr. Muhammed Murtaza
ctDNA in neoadjuvant-treated breast cancer reflects response and survival Dr. Laura van 't Veer
Panel Q&A with Drs. Dasari, Murtaza, and van 't Veer
ctDNA for Management of Solid Tumors in the Adjuvant Setting
ctDNA kinetics predict PFS and OS in EGFR TKI-treated patients with EGFR-Mutant NSCLC Dr. Philip Mack
ctDNA guiding adjuvant therapy in colon cancer Dr. Yuxuan Wang
Plasma ctDNA response is an early marker of treatment effect in advanced NSCLC Dr. Yanan Kuang
Panel Q&A with Drs. Mack, Wang, and Kuang
ctDNA Post-Treatment and MRD Surveillance of Solid Tumors
MRD detection in early stage breast cancer treatment Dr. Heather Parsons
MRD detection using plasma-only ctDNA in patients with colorectal cancer Dr. Aparna Parikh
ctDNA for MRD for treatment monitoring in advanced melanoma patients Dr. Zeynep Eroglu
Panel Q&A with Drs. Parsons, Parikh, and Eroglu
ctDNA for Treatment of Metastatic Solid Tumors
ctDNA serial analysis during progression on PD-1 blockade and later CTLA-4 rescue in patients with mismatch repair deficient metastatic colorectal cancer Dr. Pashtoon M. Kasi
Longitudinal ctDNA-based model associated with survival in metastatic NSCLC Dr. Katja Schulze
Evolution of the genomic landscape of ctDNA in metastatic prostate cancer over treatment and time Dr. Pedro Barata
Panel Q&A with Drs. Kasi, Schulze, and Barata
Challenges of ctDNA as a Biomarker
Biological/technical challenges in collection/analysis of cfDNA Dr. Abhijit Patel
ctDNA pre-analytical variables and best practices for sample collection Dr. Sarah Greytak
Evaluating the analytical validity of ctDNA sequencing assays for precision oncology Dr. Joshua Xu
Economic value of liquid biopsy for genomic profiling in advanced NSCLC Dr. Doreen A. Ezeife
Panel Q&A with Drs. Patel, Greytak, Xu, and Ezeife

Day 2

NCI Funding Initiatives for ctDNA Projects
NOFOs for ctDNA support Dr. Miguel Ossandon
Beyond DNA Mutations and Blood
HBV viral-host junction DNA in urine as a biomarker for HCC MRD and recurrence Dr. Ying-Hsiu Su
ctDNA in saliva for treatment and monitoring Dr. David Wong
Methylated microRNA biomarkers in saliva of head and neck cancer recurrence Dr. Shi-Long Lu
Collection, analysis, and clinical use of ctDNA in CSF Dr. Alexandra Miller
Panel Q&A with Dr. Su, Dr. Wong, Dr. Lu and Dr. Miller
Genomic profiling of bronchoalveolar lavage cfDNA in lung cancer Dr. Viswam Nair
Methylated cfDNA for disease subtyping and prognostics Dr. Scott Bratman
DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy Dr. Jesse Berry
ctDNA in urine to detect MRD and predict survival in bladder cancer Dr. Aadel Chaudhuri
Panel Q&A with Drs. Nair, Bratman, Berry, and Chaudhuri
Advances in Technology, Assays, and Clinical Translation
Liquid biopsies in support of NCI precision medicine initiatives Dr. Chris Karlovich
Advancing clinical applications for liquid biopsy for FGFR-positive cancers Dr. Sameek Roychowdhury
Regulatory considerations for ctDNA assays Dr. Liz Mansfield
BloodPAC protocols for analytical validation of ctDNA assays Dr. Jennifer Dickey
Panel Q&A with Drs. Karlovich, Roychowdhury, Mansfield, and Dickey

For questions about the meeting or to request copies of any of the slide presentations, contact Brian Sorg ( or the Cancer Diagnosis Program (